Galectin Therapeutics (GALT -3.4%) says it's submitted an Investigational New Drug application...

|About: Galectin Therapeutics, Inc. (GALT)|By:, SA News Editor

Galectin Therapeutics (GALT -3.4%) says it's submitted an Investigational New Drug application to the FDA to support a proposed indication of GR-MD-02 for treatment of non-alcoholic steatohepatitis with advanced fibrosis, or fatty liver disease.